Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
OSN, a roundtable discusses the management of epithelial ingrowth after LASIK, neurotrophic keratitis and Demodex blepharitis with marginal keratitis.A few thoughts after decades of treating these ...
GlobalData on MSN9h
Regeneron’s macular oedema therapy shows promise in Phase III trialIn the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback